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Microdeletions at 1q43-q44 have been described as resulting in a clinically recognizable
phenotype of intellectual disability (ID), facial dysmorphisms and microcephaly (MIC). In
contrast, the reciprocal microduplications of 1q43-q44 region have been less frequently
reported and patients showed a variable phenotype, including macrocephaly. Reports of
a large number of patients with copy number variations involving this region highlighted
the AKT3 gene as a likely key player in head size anomalies. We report four novel
patients with copy number variations in the 1q43-q44 region: one with a larger deletion
(3.7Mb), two with smaller deletions affecting AKT3 and SDCCAG8 genes (0.16 and
0.18Mb) and one with a quadruplication (1Mb) that affects the entire AKT3 gene. All
patients with deletions presented MIC without structural brain abnormalities, whereas
the patient with quadruplication had macrocephaly, but his carrier father had normal
head circumference. Our report also includes a comparison of phenotypes in cases
with 1q43-q44 duplications to assist future genotype-phenotype correlations. Our
observations implicate AKT3 as a contributor to ID/development delay (DD) and head size
but raise doubts about its straightforward impact on the latter aspect of the phenotype
in patients with 1q43-q44 deletion/duplication syndrome.
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INTRODUCTION
The 1q43-q44 microdeletion syndrome is characterized by
variable degrees of intellectual disability (ID), growth retardation,
microcephaly (MIC), corpus callosum anomalies (CCAs), seizures
(SZR), and abnormal facial features, such as round face with low-
set ears, prominent forehead and flat nasal bridge, epicanthal
folds and hypertelorism (De Vries et al., 2001; Ballif et al., 2012).
The first report of pathogenic deletions at 1q43-q44 described
a large microscopically observed deletion in a female patient
with motor and mental impairment, MIC, SZR, and several
dysmorphisms (Mankinen et al., 1976). With the development
of microarray technology, many cases with submicroscopic
deletions in this region were reported, with the consequent
identification of the genes associated with the 1q43-q44 deletion
syndrome (Boland et al., 2007; Hill et al., 2007; van Bon et al.,
2008; Orellana et al., 2009; Caliebe et al., 2010; Lall et al., 2011;
Nagamani et al., 2012; Wang et al., 2013). In Ballif et al. (2012)
defined three potentially critical regions for MIC, CCAs, and
SZR, proposing thatMIC is associated with deletions of theAKT3
(AKT serine/threonine kinase 3) gene (in 93% of the cases);
CCAs with deletions affecting ZNF238 (gene zinc finger and
BTB domain containing 18, also called ZBTB18) (in 86% of the
cases) and SZR with deletions affecting the FAM36A (also called
COX20, cytochrome c oxidase assembly factor) and HNRNPU
(heterogeneous nuclear ribonucleoprotein U) genes (in 87% of
the patients) (Ballif et al., 2012). In the same year, Nagamani
et al ruled out the implication of AKT3 gene in CCAs, because
patients 5 and 6 of their series, which have, respectively, an
intragenic deletion of AKT3 and a small deletion affecting AKT3
and SDCCAG8 (serologically defined colon cancer antigen 8)
genes, did not have CCAs (Nagamani et al., 2012). TheHNRNPU
(heterogeneous nuclear ribonucleoprotein U) and the FAM36A
(family with sequence similarity 36, also known as COX20—
cytochrome c oxidase assembly factor) genes, were proposed as
good candidates for the epilepsy and ID phenotype within the
1q43-q44 microdeletion syndrome (Thierry et al., 2012; Poot and
Kas, 2013; Leduc et al., 2017). Even though the vast majority
of the 1q43-q44 deletion cases described so far with MIC do
carry genomic rearrangements that disrupt the AKT3 gene, there
are patients described in the literature with AKT3 disruption
that do not display MIC (Ballif et al., 2012). Conversely, there
are also patients with 1q43-q44 deletion who display MIC even
though they carry deletions that do not comprise the AKT3
gene (Poot et al., 2008; van Bon et al., 2008; Ballif et al., 2012;
Raun et al., 2017). In this perspective, the description of more
patients with 1q43-q44 copy number variants (CNVs) may help
to define more precise phenotype-genotype correlations. More
recently, a deletion affecting exclusively the AKT3 gene was
described in a patient with MIC and ID and in his asymptomatic
father, being the first report of a paternally inherited pure
AKT3 deletion of incomplete penetrance (Gai et al., 2015).
In contrast with the deletions, there are only a few cases
with pure gains in the region and detailed phenotypes. Copy
number gains were described in patients with macrocephaly
together with development delay, and also paired with speech
and motor delay, hypotonia, and mild facial dysmorphisms
(Wang et al., 2013; Chung et al., 2014).
The AKT3 protein belongs to the protein kinase B (PKB/Akt)
family, involved in cell survival, proliferation and growth
(Nakatani et al., 1999). In mice, both Akt1 and Akt3 play
a role in determination of organ size. However, while Akt1
null mice have a decrease of all the organs, Akt3 null mice
have a selective 20% decrease in brain size, Akt3 being the
predominant Akt protein expressed in cortex and hippocampus.
Unfortunately, the authors showed no data concerning the brain
size in heterozygous animals, which would be relevant for the
interpretation of the findings in humans (Easton et al., 2005).
Akt3-null and heterozygous mice also have an impairment in
angiogenesis, showing a dose-dependent reduction in vessel
number (5-fold decrease in homozygous and 2.5-fold decrease
in heterozygous), an aspect of the phenotype that was never
evaluated in any of the reported patients (Corum et al., 2014).
We describe four patients with 1q43-q44 CNVs, detected by
array comparative genomic hybridization (aCGH), and attempt
to establish genotype-phenotype correlations, aiming to bring
further insight into the role of AKT3 in brain abnormalities
and ID.
METHODS
Ethical Procedures
Patients 1–3 were ascertained in the context of a larger study
of neurodevelopmental disorders in Portugal, by the referring
doctor. Clinical information was gathered in an anonymous
database authorized by the Portuguese Data Protection Authority
(CNPD). The study was approved by the ethics committee of
Center for Medical Genetics Dr. Jacinto Magalhães, National
Health Institute Dr. Ricardo Jorge. Written informed consent for
sample collection, genetic studies and publication was obtained
for all participants (signed by their parents). Informed consent
for publication of photos was obtained from the parents for
patients 1, 2, and 3 only.
Molecular Karyotyping
Genomic DNA was extracted from peripheral blood using
the Citogene R© DNA isolation kit (Citomed, Portugal) for
patient 1, QIAsymphony SP (QIAGEN GmbH, Germany) for
patients 2 and 3 and DNeasy (QIAGEN GmbH, Germany)
for patient 4. The aCGH hybridization and analysis was
performed using: Patient 1—aCGH Agilent 180K custom array
(GEO GL15397, across-array methodology; Buffart et al., 2008;
Krijgsman et al., 2013), Nexus Copy Number 5.0 software
with FASST Segmentation algorithm for data analysis; Patient 2
and 3—Affymetrix CytoScan 750K Platform (750.000 markers
distributed throughout the genome, with a medium resolution
of 8–20Kb), Chromosome Analysis Suite (ChAS 3.0) software
(Affymetrix); Patient 4—Affymetrix Cytoscan HD array.
Quantitative PCR Confirmations
Primers for quantitative PCR (qPCR) were designed using
Primer3Plus software (http://www.bioinformatics.nl/cgi-bin/
primer3plus/primer3plus.cgi) and taking into account standard
recommendations for qPCR primer development (Jovanovic
et al., 2003).
Frontiers in Genetics | www.frontiersin.org 2 February 2019 | Volume 10 | Article 58
Lopes et al. AKT3 Copy Number Changes in Neurodevelopment
For dosage quantification of AKT3, primers were designed
for exons 8, 9, and 10 of the AKT3 gene (ENSG00000117020).
The reference genes used were SDC4 (ENSG00000124145) and
ZNF80 (ENSG00000174255) localized in the 20q12-q13 and
3p12 regions, respectively (primers designed for all regions are
listed Supplementary Table 1). All qPCR reactions were carried
out in a 7,500-FAST Real Time PCR machine (Thermo Fisher
Scientific, Waltham, MA, USA) using Power SYBR Green R©
(Thermo Fisher Scientific, Waltham, MA, USA). The specificity
of each of the reactions was verified by the generation of a
melting curve for each of the amplified fragments. The primer
efficiency was calculated by the generation of a standard curve
fitting the accepted normal efficiency percentage. Quantification
was performed as described elsewhere (Hoebeeck et al., 2005). Ct
valuesTM obtained for each test were analyzed in DataAssistTM
software (Thermo Fisher Scientific, Waltham, MA, USA).
RESULTS
Clinical Description and Molecular
Findings
Patient 1 (DECIPHER #272238)
This girl was evaluated at 9 years of age for learning disabilities
andMIC [occipitofrontal circumference (OFC)−2.5 SD]. Height
and weight were at the 25th centile. She had a mildly sloping
forehead and large upper central incisors (Figure 1A). Evaluation
with the Wechsler Intelligence Scale for Children (third edition)
(Wechsler, 1991) showed a full scale IQ of 63. Brain magnetic
resonance imaging (MRI) was normal except for a discrete
global atrophy. Pregnancy and delivery were uncomplicated
at 35 weeks. OFC at birth was at the 3rd centile. Family
history is unremarkable. Parents are young, healthy and non-
consanguineous. The patient has a healthy younger brother.
Congenital cytomegalovirus infection was excluded using PCR
on the DNA obtained from the newborn metabolic disease
screening Guthrie card. Informed consent was obtained from
the child’s parents for blood sampling and genetic analyses.
Peripheral blood chromosome analysis demonstrated a normal
46,XX karyotype.
Subsequent array CGH revealed a 0.18Mb de novo deletion
at chromosome region 1q43-q44 (chr1:243,552,007–243,738,675)
containing the AKT3 and SDCCAG8 genes (Figure 2). The 1q43-
q44 deletion was confirmed by qPCR for theAKT3 gene (exons 7,
8, 9, and 10). This analysis showed the deletion breakpoint to be
located between exons 8 and 9. Analysis of the same fragments in
both parents showed that the deletion occurred de novo. Sanger
sequencing of the AKT3 coding region revealed no variants.
Patient 2 (DECIPHER # 367117)
This boy was referred for evaluation of MIC and learning
difficulties, associated with global DD in the past. Development
evaluation (Griffiths) performed in 2011 reported all
developmental areas within the low inferior range. He has
an OFC of 48 cm (P < 1, −3.9 SD) and presents slightly
dysmorphic features, including long philtrum and thin upper
lip with cupid’s bow (Figure 1B). Brain MRI performed at
age 4 years was normal. Presently, 12 years old, he attends a
school with an adapted curriculum, maintaining some learning
difficulties. He was treated with risperidone for aggressive
behavior in the past, but treatment has been discontinued. No
seizures or other behavior anomalies were reported. The patient
has a healthy older sister who was not genetically tested. Learning
difficulties were also reported in the paternal side of the family:
the father has MIC (OFC of 52.34 cm, P3), presents a rather long
face, and has mild learning difficulties; one paternal uncle can’t
read or write and has a son with learning difficulties; a sister of
the great-great-grandmother was always assistance-dependent
due to a supposed ID and MIC. Apart from the father, none of
the affected family members was genetically tested.
Array CGH revealed a 0.16Mb deletion (chr1:243,592,147–
243,749,968) affecting both the AKT3 and SDCCAG8 genes
(Figure 2). The presence of the deletion was confirmed by
qPCR for the AKT3 gene (exon 10), which also revealed
paternal inheritance.
Patient 3 (Decipher # 367116)
This boy was referred for evaluation around 3–4 months of
age for evident MIC. At 3 years of age he presented weight
and height within the normal range, but his OFC has been
in P1 (−2.6 SD) since he was 8 months old. The patient
had a hyperkinetic behavior and global DD, the language
delay being the most striking. At the age of 5 years he was
undertaking speech therapy. He didn’t know colors or numbers,
was described by parents as “clumsy” and by the teacher
as aggressive. The patient has type B bilateral tympanogram.
MRI evaluation of the brain at 3 years and 8 months old
showed a cerebral volume in accordance with a decreased
cephalic perimeter, without enlarged cerebrospinal fluid spaces
[Figure 1C, (1–3)]. The cerebral hemispheres appeared otherwise
unremarkable without noticeable malformations of cortical
development, no signs of hypoxic-ischemic or infectious lesions.
The corpus callosum was completely formed and displayed a
normal thickness. No other abnormalities were seen. There
was no evidence of significant skull abnormalities, other
than the identified smaller dimensions and a slight left
positional plagiocephaly; the electroencephalogram (EEG) was
also normal. Concerning family history, he has a maternal uncle
with epilepsy.
Array CGH revealed a 3.7Mb deletion (chr1:240,366,425–
244,111,022) (Figure 2), that proved to be de novo after qPCR
confirmation using primers for the AKT3 gene (exon 10).
Patient 4 (DECIPHER # 367118)
This boy was born at term, after an uneventful pregnancy
and delivery, with poor Apgar scores, absence of gag reflex.
Initially he presented hypotonia and apnea, having developed
seizures and dystonia at a later age (all symptoms appeared
before 5 years of age). He had a suspected IQ below 70
(although no formal evaluation was performed). He also
presents macrocephaly (with OFC of 55.5 cm at 7 years old,
corresponding to the 99th centile, +2.53 SD) and white matter
lesions of brain including thalamic lesions. aCGH revealed a
1Mb paternal quadruplication (chr1:243,415,063–244,478,355)
(Figure 2) affecting the CEP170, AKT3, SDCCAG8, and ZBTB18
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FIGURE 1 | Facial features and brain imaging of the patients. (A) Patient 1 facial features, (B) patient 2 facial features, (C) Patient 3 facial features, and MRI brain
imaging.
FIGURE 2 | Schematic representations of the CNVs found in the patients and overlap with the critical regions proposed by Ballif et al. (2012). A 2.2Mb genomic
portion encompassing cytobands 1q43-q44 is shown. RefSeq genes present within the genomic region are shown in pink and the transcriptional direction is shown
by the arrows. Shaded in gray is the proposed critical region for microcephaly (MIC) (affecting the AKT3 gene), in blue the critical region for corpus callosum anomalies
(CCAs) (affecting the ZNF238 gene) and in green the critical region for seizures (SZR) (affecting the C1ORF199 gene). Individual red horizontal bars represent deletions
and the green bar a quadruplication. In each CNV the corresponding patient is indicated.
genes; the father is phenotypically normal, even though he
is a carrier of this genetic variant. Meanwhile, patient 4
also underwent trio whole exome sequencing analysis, which
retrieved no diagnosis.
DISCUSSION
In this study, the findings in patients 1, 2, and 3 would support
the conclusion that haploinsufficiency of AKT3 gene is indeed
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associated with microcephaly. Comparing patient 6 described by
Nagamani et al. (2012) with patients 1 and 2 of this report, MIC
in our patients may be explained by the presence of a deletion
that affects a bigger portion of AKT3 (it affects the last 4 exons of
AKT3), while in the patient presented by Nagamani the deletion
only affects the last 2 exons of the gene. Patient 3 in the current
study fits quite well in the established 1q43-q44 microdeletion
syndrome regarding the phenotype and size of the deletion. This
patient, despite having a larger deletion that includes not only the
AKT3 gene but also the CEP170 gene, has evident MIC but an
apparently normal corpus callosum (Figure 1C).
The association of AKT3 copy number gains with the mirror
phenotype (macrocephaly) has also been reported in literature
(Wang et al., 2013; Chung et al., 2014; Conti et al., 2015;
Hemming et al., 2016). AKT3 is one of the genes in which
this type of mutations was found in patients with severe
overgrowth syndromes (Tatton-Brown and Weksberg, 2013).
Patient 4 in our series does present macrocephaly, supporting this
model. However, his father becomes the first reported case of a
quadruplication affecting AKT3 in an asymptomatic individual.
In 2008, van Bon et al. described a pair of sisters with ID
and MIC who inherited an AKT3-affecting deletion from their
healthy mother (patient 11 and 12 from their series; the mother
had normal IQ and normal OFC). In Ballif et al. (2012) also
described a patient series in which three patients had inherited
1q43-q44 deletions (patient 10 which has MIC, 21 which has no
information regarding OFC and 22 which doesn’t have MIC).
However, only patient 10 carried a deletion that affected AKT3
and it was maternally inherited. Reports of cases carrying 1q43-
q44 CNVs with different clinical outcomes can also be found
in the DECIPHER database (Firth et al., 2009). There are three
DECIPHER cases with AKT3-affecting deletions inherited from
parents (#317423, #252432, and #277172, the two latter ones
being reportedly healthy progenitors). However, it is important
to highlight the difficulties in interpreting this data given the
often incomplete and/or imperfect annotation of DECIPHER
entrances, particularly regarding clinical description and follow
up studies.
A possible contributing factor for the incomplete penetrance
and clinical variability associated with AKT3 genetic variants
may be somatic mosaicism. This could lead to the heterogeneous
distribution of AKT3 and/or modifying gene variants at the
somatic level. In fact, somatic mutations activating the mTOR
pathway have been shown to cause a continuum of cortical
dysplasias; ultra-deep sequencing on DNA extracted from
surgically resected brain, blood, and/or buccal samples from
patients with several (mostly focal or asymmetric) cortical
malformations led to the identification of somatic activating
mutations in several mTOR genes, including AKT3 (Lee et al.,
2012; Poduri et al., 2012; Alcantara et al., 2017; D’Gama et al.,
2017). Moreover, D’Gama et al. have proposed a “two-hit”
model in a patient with both germline and somatic TSC2 gene
mutations (D’Gama et al., 2017). The presence of “second-hit”
mutations, undetectable by targeted sequencing or present at a
level below the detection limit of the techniques commonly used,
could therefore contribute to the variability of the phenotypes
presented. This may be paricularly relevant in a situation of
increased gene dosage, which per se could have a similar but more
subtle impact than AKT3 somatic gain of function mutations.
A comparison between the “core” 1q43-q44 deletions and
duplications phenotype and the four reported cases is made
in Table 1. Of notice, the number of cases reported with
duplications affecting the AKT3 is quite reduced, making it
difficult to establish a core symptomatology.
The lack of objective phenotypic measures among 1q43-
q44 CNVs reports is an important limitation, however, to the
adequate establishment of genotype-phenotype correlations. This
was recently exposed by Raun et al who, by using more rigorous
measures of head size deviation, showed that AKT3 deletion
is associated with more severe forms of MIC, while deletions
in 1q43-q44 not affecting AKT3 resulted in less severe MIC
(probably because, as suspected before,AKT3 is unlikely to be the
only gene modulating head size at the 1q43-q44 region) (Raun
et al., 2017). However, this might not be the case for all the cases
since our patients don’t seem to follow this pattern. Patient 3 has a
MIC with−2.6 SD below the mean even though he has a deletion
altering several gene besides AKT3, whereas patient 1, who only
has the AKT3 and SDCCAG8 genes deleted, has a very similar
MIC (−2.5 SD) to that of patient 3. Patient 2 is the case with
the more severe MIC, with a SD of −3.9 even though he is the
one with the smallest deletion of our series. AKT3 partial or pure
deletions may thus be subject to incomplete penetrance and/or
differential expressivity driven by different genetic and epigenetic
backgrounds of the individuals (the resulting phenotype not
necessarily related to the deletion size). Although never reported
in the 1q43-q44 region nor affecting AKT3 specifically (the AKT3
gene is not listed in the Geneimprint database on April 2018)
(Geneimprint : Genes), imprinting alterations constitute another
mechanism of differential growth (dy)sregulation which could be
of relevance in these patients (reviewed in Choufani et al., 2013;
Geneimprint, 2018).
Recently, single nucleotide variations in ZBTB18 were
identified in two patients, one with developmental and speech
delay,MIC and dysmorphic features and the other with severe ID,
breathing disturbances and MIC without structural anomalies
(de Munnik et al., 2014; Lopes et al., 2016). This shows that
ZBTB18 mutation is sufficient to cause MIC, contradicting
the exclusive contribution of AKT3. Although, this gene is
not directly involved in the three patients with deletions here
described, we cannot exclude that the deletions occurring in
patient 1, 2, and 3 don’t have an effect in ZBTB18 expression in
the nervous system.
The minimal overlapping region of all the patients with 1q43-
q44 CNVs described in the current study encompasses only one
additional gene to AKT3: the serological defined colon cancer
antigen 8 (SDCCAG8). This gene encodes for a protein thought
to be a stable centrosomal component with a structural role in the
centrosomal architecture or themicrotubule-organizing activities
of the centrosome matrix (Kenedy et al., 2003). Mutations in
SDCCAG8 were described in patients with nephronophthisis-
related ciliopathies; even though the clinical features of those
patients include ID, a feature that is present in our patient,
the alterations causing disease in those cases are associated
with a recessive model of inheritance (Otto et al., 2010).
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Recessive variants in SDCCAG8 gene were also associated
with Bardet-Biedl syndrome and with an increased risk for
schizophrenia (Schaefer et al., 2011; Hamshere et al., 2013).
Additionally, SDCCAG8 has been described to play a role in
neuronal polarization and migration in the developing mouse
cortex (Insolera et al., 2014), which would be consistent with
the described genetic effects in humans. However, and given
the presence of SDCCAG8 deletions and quadruplication in
heterozygosity in our patients, it most likely is not contributing
to the MIC phenotype.
In summary, we describe four patients with 1q43-q44 CNVs,
three of which with outcomes that are quite consistent with
those of the “core” 1q43-q44 deletions affecting the AKT3 gene,
whereas the last (patient 4), in combination with other previously
reported cases, highlights the not so straightforward and isolated
implication of AKT3 CNVs in human OFC determination.
Despite its known biological function and the strong evidence
that AKT3 is a key gene for MIC in patients with 1q43-
q44 deletions, other factors must play a role in the arising of
the phenotype, resulting in incomplete penetrance and variable
expressivity, perhaps the consequent of different genetic or
epigenetic backgrounds of the individuals. This variability has
important implications in the clinical practice in the context of
the genetic counseling. The implication of AKT3 in head size
appears to be clear for the vast majority of the cases, even though
not absolute. For this reason, the reporting of more patients
with 1q43-q44 CNVs, their clinical and genetic features and
their variable phenotypic expressivity is important and should
be continued.
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